预约演示
更新于：2026-08-22
Vadimezan
伐地美生
更新于：2026-08-22
概要
基本信息
登录后查看时间轴
结构/序列
分子式C17H14O4 |
InChIKeyXGOYIMQSIKSOBS-UHFFFAOYSA-N |
CAS号117570-53-3 |
关联
22
项与 伐地美生 相关的临床试验NCT01071928
A Phase II Trial of Docetaxel Plus ASA404 as Second-Line Therapy in Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU09-144
EUCTR2009-016834-28-BE
An open-label, multi-center, continued access trial of investigational drug ASA404 for patients in previous ASA404 clinical trials
NCT01278758
A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and With Normal Renal Function
100 项与 伐地美生 相关的临床结果
登录后查看更多信息
100 项与 伐地美生 相关的转化医学
登录后查看更多信息
100 项与 伐地美生 相关的专利（医药）
登录后查看更多信息
439
项与 伐地美生 相关的文献（医药）2026-10-01COLLOIDS AND SURFACES B-BIOINTERFACES
A copper-engineered MnO₂ nanoplatform for potentiating STING activation and antitumor immunity in colorectal cancer
Article
作者: Sun, Jing ; Zhao, Zhenxiong ; Huang, Zhe ; Li, Jia ; Xu, Hao ; Li, Yunze ; Wang, Xiaofang
The stimulator of interferon genes (STING) pathway plays a central role in antitumor immunity but is frequently compromised by tumor hypoxia and metabolic immunosuppression within the tumor microenvironment. Here, we developed a multifunctional nano-STING inducer based on hollow manganese dioxide (MnO₂) nanoparticles loaded with the STING agonist DMXAA and surface-modified with a copper-polyphenol nanonetwork and hyaluronic acid. Upon accumulation in tumors, this nanoplatform undergoes acid-responsive degradation, enabling controlled DMXAA release and STING activation. Concurrently, MnO₂ catalyzes tumor-derived hydrogen peroxide to generate oxygen, alleviating hypoxia and suppressing lactate production, thereby relieving lactate-mediated inhibition of STING signaling. In addition, released copper ions promote tumor cell death with immunogenic features, further facilitating immune activation. In an orthotopic colorectal cancer model, MnO₂@Cu-HA robustly activates intratumoral STING signaling, reduces immunosuppressive myeloid and regulatory T cell populations, promotes dendritic cell maturation and macrophage reprogramming, and enhances CD8⁺ T cell infiltration. Collectively, this nano-STING inducer remodels the immunosuppressive tumor microenvironment and elicits coordinated innate and adaptive antitumor immune responses, providing an effective strategy to overcome metabolic and hypoxic barriers to STING-based cancer immunotherapy.
2026-08-01CARBOHYDRATE POLYMERS
A flexible antigen-presenting cell targeting lentinan immunomodulator promotes stimulator of interferon gene-driven cancer therapy
Article
作者: Zhu, Qianli ; Deng, Hongping ; Miao, Jiaqian ; Ju, Jingxuan ; Zhang, Minxia ; Cheng, Xiangshu ; Jin, Mingming ; Guo, Jiaxuan ; Wang, Junjie ; Xu, Li ; Ge, Guangbo
Activation of antigen-presenting cells (APCs) via the stimulator of interferon genes (STING) signaling pathway is a promising strategy for cancer therapy. However, the rational engineering of a targeted synergistic immunomodulator and its morphological impact for STING activation remains elusive. Herein, we developed an APC-targeting lentinan-STING agonist immunomodulator with flexible and assembled morphological forms for cancer therapy. Lentinan (LN) exhibited intrinsic APC targeting and immune activation characteristics, and the conjugation between lentinan and a STING agonist (DMXAA) not only decreased the toxicity of lentinan toward APC cells, but also realized synergistic STING activation via lentinan and DMXAA. The flexible and assembled morphological forms were readily achieved by tuning the DMXAA loadings of the immunomodulators, denoted as LN-DMXAA(L) and LN-DMXAA(H). The flexible immunomodulator LN-DMXAA(L) with lower DMXAA loading potently induced macrophage reprogramming and dendritic cell maturation as compared with the assembled immunomodulator LN-DMXAA(H) and free drug DMXAA. In a 4 T1 tumor-bearing mice model, LN-DMXAA(L) significantly boosted tumor growth inhibition rate to 78.3% as compared with 46.2% for LN-DMXAA(H) and 27.8% for DMXAA by activating APCs and CD8+ T cells via the STING signaling pathway. Thus, this work highlights the conception of a flexible immune-activating polysaccharide-STING agonist immunomodulator for cancer therapy.
2026-08-01INTERNATIONAL IMMUNOPHARMACOLOGY
rhFGF21-loaded P hydrogel promoted diabetic wound repair by regulating the inflammatory cytokine expression and phagocytic function of macrophages via the STING-mediated autophagy pathway
Article
作者: Qiu, Ruiying ; Chen, Jun ; Wu, Junyi ; Wang, YiRan ; Li, Jiana ; Ye, Shasha ; Lin, Jingjing ; Zhao, Yeli
Macrophage dysfunction serves as a pivotal factor in the delayed healing of diabetic wounds. Fibroblast growth factor 21 (FGF21) inhibits inflammation and promotes tissue regeneration, but it's limited by short half-life and poor stability. Poloxamer (P) hydrogel is a sustained drug delivery system. Therefore, this study aimed to investigate the role of macrophage dysfunction on the promotion of wound healing by rhFGF21-P hydrogel in type 2 diabetes mellitus (T2DM) murine models and murine peritoneal macrophages (MPMs) stimulated with high glucose and LPS (HG + LPS) for in vitro studies. P hydrogel sustained the release and enhanced the stability of rhFGF21. RhFGF21-P administration accelerated diabetic wound closure and reduced the levels of TNF-α, IL-6, MCP-1 and MIP-2 in diabetic mouse serum and skin tissues as well as in HG + LPS-stimulated MPMs. RhFGF21-P attenuated the fluorescence intensity of F4/80 and increased the level of autophagy in T2DM wound mice. RhFGF21 enhanced phagocytic capacity and the expression of LC3II protein in HG + LPS-stimulated MPMs, and the regulation of rhFGF21 in inflammatory cytokines and phagocytosis was reversed by autophagy inhibitors (3MA and CQ). In addition, rhFGF21 downregulated the levels of STING in vivo and in vitro. Furthermore, rhFGF21 increased the expression of LC3II protein, inhibited the mRNA levels of inflammatory cytokines (TNF-α and IL-6) and enhanced phagocytosis in HG + LPS-treated MPMs, but these effects were reversed by the STING agonist Vadimezan. These results demonstrated that rhFGF21-P promoted diabetic wound healing through inhibiting the expression of inflammatory cytokines and enhancing phagocytic function of macrophages via the modulation of STING-mediated autophagy.
100 项与 伐地美生 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非小细胞肺癌IIIB期 | 临床3期 | 美国 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 比利时 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 加拿大 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 法国 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 德国 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 匈牙利 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 意大利 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 波兰 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 西班牙 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 瑞士 | 2008-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 广泛期小细胞肺癌 一线 | 56 | 鏇膚遞構鹹憲齋窪顧廠(齋窪廠製廠憲顧醖鑰廠) = 壓餘窪艱鹹獵糧製淵選 繭簾願鏇衊鏇鑰夢鑰艱 (淵夢廠廠鑰糧衊艱膚廠 ) 更多 | - | 2013-01-01 | ||
临床1期 | 7 | 窪膚蓋顧襯壓網鏇簾範(廠鑰窪範鑰憲餘鹽鹹簾) = 憲構築築壓獵鏇淵範壓 餘選餘襯製顧鏇願鏇膚 (範網廠壓遞鬱齋齋鬱憲 ) 更多 | - | 2012-04-15 | |||
ASCO2011 人工标引  | 临床3期 | - | Carboplatin/Paclitaxel | 範顧簾蓋壓遞網鹹憲襯(獵簾製醖獵願餘夢齋襯) = 製構膚醖選憲齋鹽壓襯 衊餘糧積廠襯窪鏇廠廠 (蓋構簾憲鑰願窪窪膚夢 ) 更多 | 不佳 | 2011-05-20 | |
Carboplatin/Paclitaxel + ASA404 | 範顧簾蓋壓遞網鹹憲襯(獵簾製醖獵願餘夢齋襯) = 構蓋網壓網鑰鹽鹽鏇觸 衊餘糧積廠襯窪鏇廠廠 (蓋構簾憲鑰願窪窪膚夢 ) 更多 | ||||||
临床2期 | 108 | CP alone | 製齋餘範衊醖夢鹹糧築(齋簾範壓選糧艱鏇憲鬱) = 齋鹹鏇廠餘膚簾獵糧鬱 餘範獵繭膚積積獵築膚 (廠齋製構齋積鑰膚蓋醖 ) | - | 2010-12-01 | ||
CP + ASA404 | 製齋餘範衊醖夢鹹糧築(齋簾範壓選糧艱鏇憲鬱) = 顧願獵鑰繭窪廠鬱遞膚 餘範獵繭膚積積獵築膚 (廠齋製構齋積鑰膚蓋醖 ) | ||||||
临床3期 | - | 築憲觸簾窪鑰鑰築夢繭(糧廠鑰繭襯觸遞觸膚廠) = 醖築襯獵願襯觸繭願糧 夢醖夢築蓋獵觸獵壓鏇 (範憲窪醖夢廠製衊鬱遞 ) 更多 | - | 2010-04-15 | |||
築憲觸簾窪鑰鑰築夢繭(糧廠鑰繭襯觸遞觸膚廠) = 簾鹹鑰餘鬱衊顧遞餘遞 夢醖夢築蓋獵觸獵壓鏇 (範憲窪醖夢廠製衊鬱遞 ) | |||||||
临床2期 | - | 鏇積築廠衊艱廠積鹹夢(膚艱蓋繭夢製廠艱觸淵) = 齋選鹽糧範糧壓憲夢壓 膚膚簾獵衊齋醖鏇繭鏇 (膚艱鑰糧積鹹夢繭鹽築 ) 更多 | 积极 | 2008-05-20 | |||
Docetaxel alone | 鏇積築廠衊艱廠積鹹夢(膚艱蓋繭夢製廠艱觸淵) = 齋顧獵憲壓簾鹹遞獵構 膚膚簾獵衊齋醖鏇繭鏇 (膚艱鑰糧積鹹夢繭鹽築 ) 更多 | ||||||
临床2期 | - | 夢範齋觸齋觸獵獵醖獵(廠繭夢遞鏇鏇夢鏇獵膚) = 構襯構鏇鹹糧網獵淵築 築淵鹹簾鏇鹹遞積蓋範 (築獵醖齋積窪襯願齋壓 ) | - | 2008-05-20 | |||
CP alone | 夢範齋觸齋觸獵獵醖獵(廠繭夢遞鏇鏇夢鏇獵膚) = 餘製製憲餘遞鑰繭願鹹 築淵鹹簾鏇鹹遞積蓋範 (築獵醖齋積窪襯願齋壓 ) | ||||||
临床1期 | 15 | 壓遞襯糧夢壓糧糧製蓋(齋繭鑰餘遞選製積蓋醖) = 衊獵糧獵壓選選築窪簾 網壓觸鑰艱製簾廠蓋鹽 (夢築選淵繭顧製獵築糧 ) | - | 2006-03-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用